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Abstract: Tumor necrosis factor alpha (TNF-alpha) is an important pro-inflammatory 
cytokine implicated in the pathogenesis of psoriatic arthritis. We have performed a   
case-control association study of three TNF-alpha gene polymorphisms in a group of 
Romanian psoriatic arthritis patients versus ethnically matched controls. A second group of 
patients with undifferentiated spondyloarthritis was used in order to look for similarities in 
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the genetic background of the two rheumatic disorders. The −857C/T polymorphism was 
associated with susceptibility to psoriatic arthritis in our population at the individual level 
(p = 0.03, OR 1.65, 95% CI 1.05–2.57) and in combined haplotypes with the −238G/A and  
−308G/A SNPs. Regarding the investigated polymorphisms and derived haplotypes, no 
potential association was found with the susceptibility to undifferentiated spondyloarthritis 
in Romanian patients. 
Keywords: tumor necrosis factor alpha (TNF-alpha); psoriatic arthritis; single nucleotide 
polymorphism (SNP); undifferentiated spondyloarthritis 
 
1. Introduction 
The regulatory proteins known as cytokines have an important role in the pathogenesis of 
inflammatory diseases [1,2]. Among them, tumor necrosis factor-alpha (TNF-alpha) was intensively 
studied in relation with these disorders. Although anti-TNF-alpha therapies represent a major step in 
the treatment of many inflammatory conditions [3–5], the pathological involvement of TNF-alpha is 
not completely understood. 
Psoriatic arthritis (PsA) is a rheumatic disease that belongs to the group of spondyloarthritides. The 
disease is characterized by inflammatory arthritis, localized at the axial skeleton and/or peripheral 
joints, which is accompanied in most cases by psoriatic skin lesions [6]. Given the pattern of 
inheritance, PsA is considered a genetically complex multigenic disease [7]. Single nucleotide 
polymorphisms (SNPs) of the TNF-alpha gene showed association with psoriatic arthritis in some 
populations [8,9], but no association in others [10,11]. TNF-alpha is located in the major 
histocompatibility complex (MHC) region on the chromosome 6p21.3, region that showed the 
strongest signal of association in the genome-wide association study that included psoriatic arthritis 
patients [12]. 
Undifferentiated spondyloarthritis (USpA) is the second most common subtype of seronegative 
spondyloarthritides, but it is less studied from the point of view of genetic association compared with 
other diseases in this group, like ankylosing spondylitis and psoriatic arthritis [13,14]. An association 
of TNF-alpha -308G/A polymorphism with susceptibility to USpA was found in a group of Mexican 
patients [15]. 
Our aim in this study was to investigate the association of three TNF-alpha gene promoter 
polymorphisms with psoriatic arthritis in a Romanian group of patients. A second cohort of 
undifferentiated spondyloarthritis patients was included in the study in order to find similarities in the 
genetic background of the two inflammatory diseases. This is the first study of TNF-alpha SNPs in a 
Romanian group of spondyloarthritides. 
2. Results and Discussion 
We have performed a case-control association study of TNF-alpha gene single nucleotide 
polymorphisms in a group of Romanian psoriatic arthritis patients versus ethnically matched controls. Int. J. Mol. Sci. 2011, 12 
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A second group of patients with undifferentiated spondyloarthritis was used in order to look for 
similarities in the genetic background of the two rheumatic disorders. 
None of the three TNF-alpha polymorphisms showed a departure from Hardy-Weinberg 
equilibrium in the investigated groups. The data for controls were compared with data available in the 
database www.allelefrequencies.net for Caucasian populations. The genotype frequencies of the   
−308G/A and −238G/A polymorphisms were in the range of those reported for other populations. The 
rare genotype −238AA was not present in the investigated Romanian control group or patients. For the 
−857C/T polymorphism, only two Caucasian populations have been reported in the database, with 
frequencies of CC genotype significantly higher than ours (82% versus 67%, p = 0.004, for a 
population from Norway, respectively 88% versus 67%, p = 0.0001, for a Canadian population). 
The analysis of alleles and genotypes distribution of each of the individual SNPs in cases compared 
with controls revealed a positive uncorrected association of the −857C/T polymorphism with psoriatic 
arthritis, but not with undifferentiated spondyloarthritis (Table 1). The minor allele T was more 
prevalent in PsA patients than in controls (p = 0.03) and the genotypes bearing T allele were 
significantly more frequent in PsA patients (p = 0.01). The distribution of the TNF-alpha −238G/A and  
−308G/A polymorphisms was not significantly different between patients and controls in both   
disease groups. 
Table 1. Genotype distribution and allele frequencies of the tumor necrosis factor   
(TNF)-alpha gene promoter polymorphisms for psoriatic arthritis (n = 86), undifferentiated 
spondyloarthritis (n = 79) and controls (n = 147). OR, odd ratio; CI, 95% confidence 
interval for OR. * Data available for 142 control subjects. 
SNP Group  Genotype  Minor  Allele 
Frequency 
p Value  OR/CI (95%) 
TNF-857 * 
rs 1799724 
 
PsA 
Controls 
USpA 
CC 
46 (53.5%) 
95 (67%) 
47 (59.7%) 
CT 
32 (37.2%) 
41 (28.8%) 
27 (34%) 
TT 
8 (9.3%) 
6 (4.2%) 
5 (6.3%) 
T 
27.9% 
19% 
23.4% 
 
0.03 
 
0.27 
 
1.65 (1.05–2.57) 
 
1.3 (0.81–2.08) 
TNF-308 * 
rs 1800629 
 
PsA 
Controls  
USpA 
GG 
71 (82.6%) 
107 (75.4%) 
62 (78.6%) 
GA 
13 (15.1%) 
30 (21.1%) 
16 (20.2%) 
AA 
2 (2.3%) 
5 (3.5%) 
1 (1.2%) 
A 
10% 
14% 
11.4% 
 
0.24 
 
0.46 
 
0.66 (0.36–1.22) 
 
0.78 (0.43–1.42) 
TNF-238 
rs 361525 
 
PsA 
Controls 
USpA 
GG 
78 (90.7%) 
141 (96%) 
73 (92.4%) 
GA 
8 (9.3%) 
6 (4%) 
6 (7.6%) 
AA 
0 
0 
0 
A 
4.6% 
2% 
7.6% 
 
0.15 
 
0.35 
 
2.34 (0.8–6.56) 
 
1.89 (0.6–5.97) 
The analysis of the three subgroups of PsA patients revealed similar distribution of the investigated 
polymorphisms in oligoarthritis and polyarthritis patients and a high frequency of −857T allele in the 
subgroup of spondylitis patients (30.3% versus 19% in controls), but this result did not reach a 
statistical significance (p = 0.07). 
The correlation coefficient between each pair of SNPs (r2) was below 0.1 (Table 2), so all the three 
investigated SNPs were included in the haplotype analysis. Four haplotype combinations between the Int. J. Mol. Sci. 2011, 12 
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three polymorphic loci of TNF-alpha were observed in each group (Table 3). The haplotype 
−857C/−308G/−238A exhibited a frequency of only 2% in controls and was eliminated from further 
analysis. The frequency of −857T/−308G/−238G haplotype tends to increase significantly in PsA 
patients with respect to healthy controls (p = 0.02). The analysis of the estimated haplotypes between 
pairs of SNPs (Table 3) revealed a positive association of those combinations that contains the minor 
−857T allele (−857T/−308G, p = 0.02 and −857T/−238G, p = 0.02) and a negative association of 
−857C/−238G haplotype (67% in cases versus 78% in controls, p = 0.006). A negative association of 
this haplotype (−857C/−238G) was found also in the PsA patients with spondylitis (64% in cases 
versus 78% in controls, p = 0.01). No association of any of the estimated haplotypes was found in the 
USpA group. 
Table 2. Results of linkage disequilibrium statistics for TNF-alpha polymorphisms for 
Romanian psoriatic arthritis (PsA) patients and controls. 
  TNF-238G/A TNF-308G/A TNF-857C/T 
TNF-238G/A 1  0.00836571  0.0151408 
TNF-308G/A   1  0.0740285 
TNF-857C/T     1 
Table 3. TNF-alpha haplotypes in PsA patients and controls. 
Haplotype Haplotype  Frequency  p Value 
857/308/238 
CGA 
CAG 
TGG 
CGG 
PsA  
0.04 
0.09 
0.27 
0.57 
Controls 
0.02 
0.14 
0.19 
0.64 
 
0.12 
0.18 
0.02 
0.12 
857/308 
CA 
TG 
CG 
 
0.09 
0.27 
0.62 
 
0.14 
0.19 
0.66 
 
0.18 
0.02 
0.3 
857/238 
CA 
TG 
CG 
 
0.04 
0.27 
0.67 
 
0.02 
0.19 
0.78 
 
0.12 
0.02 
0.006 
Tumor necrosis factor alpha is an important pro-inflammatory cytokine that is considered to play an 
essential role in driving the cytokine cascade at sites of inflammation both of the skin and joints of PsA 
patients [16]. High levels of TNF-alpha found in the inflammatory infiltrate of the synovium and in 
membranes of the affected joints [17–19] made TNF-alpha an attractive candidate for genetic research 
and for biological therapies. PsA patients showed decreased serum levels of TNF-alpha during 
efficacious treatment with TNF blocking agents [16]. A possible mechanism of TNF-alpha 
pathological contribution to the development of PsA could be through interleukine 23 (IL-23) that has 
a leading role in the development of cells producing TNF-alpha. SNPs of the gene coding for p40 
subunit of IL-23 show association with both psoriatic arthritis and psoriasis in recent studies [20]. Int. J. Mol. Sci. 2011, 12 
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Studies on TNF-alpha gene polymorphisms in relation to psoriatic arthritis generated conflicting 
results in different populations. No association was found in Jewish and Spanish populations [10,21]. 
We have found that TNF-alpha −857C/T polymorphism, previously reported as being associated with 
PsA in a German group [22], also represents a risk factor for this condition in the Romanian 
population. However, this result looses statistical significance if the correction for multiple testing is 
applied. Significant associations were found between −238G/A polymorphism and PsA in the German 
and Canadian populations [8,9], an association that was not confirmed in the present study. Moreover, 
the relation of strong linkage disequilibrium found between the three TNF-alpha SNPs in a German  
group [22] was not present in the Romanian cohort. These variations from one study to another might 
reflect the differences in the genetic background of the populations, but also the variability of the 
disease itself. In our PsA group, the spondylitis and polyarthritis patterns were about 37% each, the 
rest being oligoarthritis. In the German PsA group, only 19.2% of cases had spondylitis and about 69% 
had polyarthritis. In the Canadian study, 61% of patients presented polyarthritis, 5.2% spondylitis and 
the rest oligoarthritis and other arthritis patterns. 
We have identified several haplotypes associated with the susceptibility of this disease and also a 
haplotype associated with a specific pattern of arthritis (spondylitis). To our knowledge, this 
association has not been previously found in any population. Future studies are needed to elucidate the 
precise contribution of this genomic region to the pathogenesis of psoriatic arthritis. 
Regarding undifferentiated spondyloarthritis, the investigated TNF-alpha polymorphisms did not 
show any association in this Romanian group of patients. The inflammatory arthritis of this disorder 
seems to have different genetic causes compared with psoriatic arthritis in our population. The 
association found in the Mexican population
15 could be the result of a different ethnic background. 
3. Experimental Section 
3.1. Subjects 
Two groups consisting of 86 unrelated Romanian patients with psoriatic arthritis (M/F 42/44, mean 
age 51 years) and 79 Romanian patients with undifferentiated spondyloarthritis (M/F 30/49, mean age 
37.5 years) were recruited from two rheumatology centers (“St. Maria” Hospital and   
“I.C. Cantacuzino” Hospital, Bucharest, Romania) between 2007 and 2010. The PsA patients satisfied 
the Classification criteria for the diagnosis of Psoriatic Arthritis (CASPAR) [23]. Among the psoriatic 
arthritis patients, 22 subjects (26%) had peripheral arthritis with less than 5 joints affected 
(oligoarthritis), 32 individuals (37%) had more than five joints affected (polyarthritis) and 32 subjects 
(37%) presented arthritis with axial involvement (spondylitis). All undifferentiated spondyloarthritis 
patients fulfill the European Spondyloarthropathy Study Group diagnostic criteria for 
spondyloarthritides [24], but not the specific criteria for any other disease in this group. 
A cohort of healthy Romanian individuals from “Prof. Dr. C. T. Nicolau” National Institute of 
Blood Transfusion, Bucharest, Romania (potential organ donors, n = 147) was used as control group. 
The controls matched the patient groups for sex ratio and mean age (1.5 and 39 years, respectively). 
None of the control subjects had a history of a diagnosed rheumatic condition or psoriasis. Int. J. Mol. Sci. 2011, 12 
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The study was approved by the local ethics committee. The details were explained to all patients 
and controls and consent for genetic screening was obtained. 
3.2. Genotyping of TNF-Alpha Promoter Polymorphisms 
The genomic DNA was extracted from venous blood with the Qiagen Blood Mini Kit (Qiagen, 
Hilden, Germany) according to the manufacturer protocol. 
Patients and controls were genotyped for three TNF-alpha gene promoter polymorphisms:   
−857C/T (rs 1799724), −308G/A (rs 1800629) and −238G/A (rs 361525). The genotyping of all three 
polymorphisms was performed by allelic discriminating TaqMan Real-Time PCR with TaqMan SNP 
Genotyping Assays according to manufacturer protocol (Applied Biosystems, USA) on a 7300 Real 
Time PCR System (Applied Biosystems, USA). 
3.3. Statistical Analysis 
Alleles and genotypes frequencies of all SNPs were obtained by direct counting. The   
Hardy-Weinberg equilibrium was tested using the Chi-square test. In order to evaluate the possibility 
of the haplotypes’ reconstruction between the investigated SNPs, the level of linkage disequilibrium 
(LD) was studied by calculating the correlation coefficient between each pair of loci (r2). The 
association test for the disease trait was performed using the Fisher’s exact test and also with a logistic 
regression model. The association tests for each polymorphism and haplotype, the LD and HWE tests 
and the haplotype frequency estimations were performed with the software package PLINK v 1.07 [25] 
and p values ≤0.05 were considered statistically significant. 
4. Conclusions 
The present study shows that TNF-alpha gene promoter polymorphism −857C/T is associated with 
the susceptibility to psoriatic arthritis in Romanian population at the individual level and in combined 
haplotypes with −238G/A and −308G/A SNPs. These findings require further validation on a larger 
group of patients. No potential association was found regarding the three investigated polymorphisms 
and derived haplotypes with susceptibility to undifferentiated spondyloarthritis in Romanian patients. 
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